Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001354532 | SCV004811022 | uncertain significance | not provided | 2024-02-01 | criteria provided, single submitter | clinical testing | FLG: PM2, BP4 |
Department of Pathology and Laboratory Medicine, |
RCV001354532 | SCV001549174 | likely benign | not provided | no assertion criteria provided | clinical testing | The FLG p.Ser2649Thr variant was not identified in the literature nor was it identified in ClinVar, Cosmic or LOVD 3.0. However, this missense variant is found in a gene for which the primary cause of disease is truncating variants. The variant was identified in dbSNP (ID: rs757903351) and in control databases in 49 of 231176 chromosomes at a frequency of 0.000212 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: European (Finnish) in 11 of 21400 chromosomes (freq: 0.000514), Other in 3 of 6154 chromosomes (freq: 0.000488) and European (non-Finnish) in 35 of 103444 chromosomes (freq: 0.000338); it was not observed in the African, Latino, Ashkenazi Jewish, East Asian and South Asian populations. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. The p.Ser2649 residue is conserved in mammals however four out of five computational analyses (PolyPhen-2, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. |